-
2021 ICML treatment options for follicular lymphoma
Time of Update: 2021-08-18
Research Methods This retrospective study included 16 centers under GELTAMO, who received induction therapy with BR or R-CHOP as the first line, and subsequently received rituximab monotherapy for maintenance therapy in FL patients, to evaluate the efficacy and safety of the treatment plan Sex .
-
How to diagnose and treat inflammatory bowel disease with anemia?
Time of Update: 2021-08-18
Diagnosis of IBD-related anemia is recommended by the European Organization for Crohn’s Disease and Colitis (ECCO) guidelines in 2021, when inflammation is not present (ie lack of biological indicators such as CRP, ESR, white blood cell count, or clinical evidence such as diarrhea, blood in the stool, or endoscopy) Inflammation is confirmed by manifestations, etc.
-
Acute myocardial infarction was admitted to the hospital, it turned out to be the fault of this rheumatism!
Time of Update: 2021-08-18
Elderly women, who have had multiple traditional cardiovascular risk factors in the past, were admitted to the hospital because of chest pain and right upper limb pain.
Case summary In this case, the patient has thrombosis in multiple organs, and then consider the diagnosis of CAPS .
-
What should I do if the elderly are prone to iron deficiency anemia?
Time of Update: 2021-08-14
Expert consensus on prevention and treatment of traditional Chinese medicine in communities at high risk of iron-deficiency anemia in the elderly[J].
Expert consensus on prevention and treatment of traditional Chinese medicine in communities at high risk of iron-deficiency anemia in the elderly[J].
-
Lancet Haematol: Venetoclax combined with intensive chemotherapy in the treatment of AML or high-risk MDS
Time of Update: 2021-08-14
For newly diagnosed patients with acute myeloid leukemia or high-risk myelodysplastic syndromes, adding Venetoclax to intensive chemotherapy is safe and effective, can produce a high rate of durable MRD negative remission, and improve event-free survival and overall survival Rate .
-
Leukemia: Donor-derived NK cells can reduce the recurrence rate of cancer patients after allogeneic hematopoietic stem cell transplantation
Time of Update: 2021-08-14
Immune reconstitution of treated patientsImmune reconstitution of treated patientsAll in all, the results of the study revealed that it is safe to give donor-derived expanded NK cells after allogeneic hematopoietic stem cell transplantation, and is related to the early post-transplantation NK cell-led immune reconstitution, disease recurrence rate and the improvement of patients' DFS .
-
Leukemia: Overactivation of CXCR4 drives the occurrence and development of chronic lymphocytic leukemia
Time of Update: 2021-08-14
LymphomaIn this study, the researchers constructed a gain-of-function CXCR4 mutation (CXCR4 C1013G) mouse model with excessive activation of CXCR4 signaling, and identified CXCR4 as a key activator of multiple key carcinogenic pathways .
-
JASN: Association between lead concentration in community water system and hemoglobin concentration in patients with advanced CKD
Time of Update: 2021-08-14
It can be seen that this national analysis linking EPA water supply records with patient data shows that even if the lead content in the community water system in the United States is low, it is also related to the lower hemoglobin level and higher ESA of patients with end-stage renal disease.
-
Popular science stickers: peripheral T-cell lymphoma (PTCL)
Time of Update: 2021-08-14
Peripheral T Cell Lymphoma (Not Otherwise Specified, PTCL-NOS) is the most common histological subtype .
Peripheral T Cell Lymphoma (Not Otherwise Specified, PTCL-NOS) is the most common histological subtype .
Peripheral T Cell Lymphoma (Not Otherwise Specified, PTCL-NOS) is the most common histological subtype .
-
Lancet: The bispecific antibody Teclistamab is expected to become a new treatment for relapsed/refractory multiple myeloma!
Time of Update: 2021-08-14
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, singlearm, phase 1 study .
1016/S1470-2045(21)00376-4Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, singlearm, phase 1 study in this message
-
"The Lancet": The total remission rate is as high as 97%, and the early results of the new CAR-T therapy for multiple myeloma are eye-catching
Time of Update: 2021-08-12
Studies have shown that a single infusion of cilta-cel shows early, deep and lasting remission in patients with relapsed or refractory multiple myeloma .
75×106 CAR-positive live T cells/kg) cilta-cel infusion, the overall response rate was 97%, of which 65 cases (67%) achieved complete remission, and the median time to first remission was 1 month .
-
Nature sub-Journal Wei Haiming/Tian Zhigang of University of Science and Technology of China reveals that tocilizumab can potentially treat preimplantation syndrome
Time of Update: 2021-08-12
iNature unrelated cord blood transplantation (UCBT) is an effective method for the treatment of hematopoietic diseases .
HLA-Haploidentical transplantation is spreading rapidly around the world, and cord blood (CB) is also a good alternative source of hematopoietic stem cells .
-
NK cells combined with CD38 antibody to treat multiple myeloma
Time of Update: 2021-08-12
Recent popular reports from Yimaike ★Dry goodsCAR-T therapy shows great power, and the cellular immune industry welcomes market opportunities ★The most potential drug transporter-exosomes Yimai New Observation Click on the picture and register now July 7, 2021 Japan/MedClub News/--XNK Therapeutics recently announced that the Phase II clinical study of its autologous natural killer (NK) cell therapy candidate CellProtect has been included in the first patient.
-
[Summary] FDA approved new drugs and new programs for hematological malignancies in the first half of 2021
Time of Update: 2021-08-12
For more details, please click: FDA Update | Approval of isatuximab-irfc for the treatment of multiple myeloma patients when combined with carfilzomib and dexamethasone, the recommended dose of Isatuximab-irfc is 10mg/kg, intravenous infusion once a week for 4 weeks , And then every two weeks until the disease progresses or intolerable toxicity occurs .
-
Professor Wang Jingbo: Leukemia can be transplanted without remission
Time of Update: 2021-08-12
"The Department of Hematology, Aerospace Center Hospital, under the leadership of Director Wang Jingbo, has become an important new force in the diagnosis and treatment of relapsed and refractory leukemia in China.
-
Big coffee interview with Professor Cai Qingqing on the progress of chidamine combined regimen in the treatment of peripheral T-cell lymphoma
Time of Update: 2021-08-12
Professor Qingqing Cai This study compared the efficacy of chidamide-containing regimens and chemotherapy alone in the second-line treatment of PTCL .
In the retrospective study of the first-line treatment of PTCL by Professor Qingqing Cai, we compared the CHOP combined with Chidamide regimen and the CHOP regimen .
-
Professor Song Yuqin: Experience sharing of Beijing Cancer Hospital, to be the pioneer of CAR-T standardized full-process management
Time of Update: 2021-08-12
Yimaitong is honored to invite Professor Song Yuqin, deputy director of the Lymphoma Department of Peking University Cancer Hospital, to share his research results and clinical experience on the standardized management of the entire process of CAR-T treatment .
-
Sirolimus in the treatment of relapsed/refractory immune thrombocytopenia
Time of Update: 2021-08-11
The results of a single-center, prospective, one-arm study from Xinqiao Hospital indicate that sirolimus can promote and rebuild peripheral tolerance by regulating the T, B and myeloid cell subsets of patients with refractory ITP.
-
Sanofi's $1 billion bet on new targets, which strong doctor on the multiple myeloma circuit, Mai Meng broke the news
Time of Update: 2021-08-10
Click on the picture and register now July 9, 2021 Japan/MedClub News/--Recently, Eureka Therapeutics and Memorial Sloan Kettering Cancer Center (MSKCC) and Sanofi reached a license agreement on the "non-CAR use of human GPRC5D binding domain", aiming to develop potential Multiple myeloma therapy .
-
JAMA Oncology Shanghai Jiaotong University and other institutions cooperated, Academician Pei Zhengkang revealed that dasatinib is more effective in treating children with Philadelphia chromosome-positive acute lymphoblastic leukemia
Time of Update: 2021-08-10
iNature requires a randomized clinical trial to determine whether the second-generation Abl-tyrosine kinase inhibitor dasatinib (dasatinib) is better than the first-generation inhibitor imatinib mesylate in the treatment of children with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) is more effective .
